Jia Jie Biomedical Co Ltd Net Assets
Jia Jie Biomedical Co Ltd net assets. Based on the latest financial reports, Jia Jie Biomedical Co Ltd (4109) has net assets worth NT$1.70 Billion TWD (≈ $53.61 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.92 Billion ≈ $60.57 Million USD) and total liabilities (NT$220.89 Million ≈ $6.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Jia Jie Biomedical Co Ltd (4109) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.70 Billion |
| % of Total Assets | 88.51% |
| Annual Growth Rate | 5.71% |
| 5-Year Change | 83.33% |
| 10-Year Change | 78.07% |
| Growth Volatility | 16.93 |
Net Assets of Jia Jie Biomedical Co Ltd (2015–2025)
Net assets of Jia Jie Biomedical Co Ltd from 2015 to 2025. This chart illustrates how Jia Jie Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 4109 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Jia Jie Biomedical Co Ltd (2015–2025)
The table below shows the annual net assets of Jia Jie Biomedical Co Ltd from 2015 to 2025. For live market cap and overall valuation, see Jia Jie Biomedical Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.71 Billion ≈ $54.00 Million |
+26.10% |
| 2024-12-31 | NT$1.36 Billion ≈ $42.82 Million |
+27.00% |
| 2023-12-31 | NT$1.07 Billion ≈ $33.72 Million |
+15.83% |
| 2022-12-31 | NT$923.96 Million ≈ $29.11 Million |
-1.17% |
| 2021-12-31 | NT$934.93 Million ≈ $29.46 Million |
+2.97% |
| 2020-12-31 | NT$907.97 Million ≈ $28.61 Million |
+30.67% |
| 2019-12-31 | NT$694.88 Million ≈ $21.89 Million |
-2.70% |
| 2018-12-31 | NT$714.19 Million ≈ $22.50 Million |
+2.09% |
| 2017-12-31 | NT$699.60 Million ≈ $22.04 Million |
-27.32% |
| 2016-12-31 | NT$962.54 Million ≈ $30.33 Million |
-2.10% |
| 2015-12-31 | NT$983.23 Million ≈ $30.98 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jia Jie Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 97.7% over the analyzed period, indicating profitable operations and earnings retention.
Jia Jie Biomedical Co Ltd Net Assets Breakdown (December 2025)
Jia Jie Biomedical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$207.82 Million | 12.34% |
| Other Components | NT$1.48 Billion | 87.66% |
| Total Equity | NT$1.68 Billion | 100.00% |
Jia Jie Biomedical Co Ltd Competitors by Market Cap
The table below lists competitors of Jia Jie Biomedical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinsin Pharmaceutical Co. Ltd
KQ:002800
|
$39.89 Million |
|
RENALYTIX PLC LS-0025
F:2O9
|
$39.89 Million |
|
East Asia Holdings Investment Limited
KQ:900110
|
$39.91 Million |
|
Staatl. Mineralbrunnen AG
MU:SLB
|
$39.92 Million |
|
RFTech Co. Ltd
KQ:061040
|
$39.83 Million |
|
Dish TV India Limited
NSE:DISHTV
|
$39.82 Million |
|
TradeDoubler AB
ST:TRAD
|
$39.81 Million |
|
Xos Inc
NASDAQ:XOS
|
$39.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jia Jie Biomedical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,331,016,000 to 1,683,808,000, a change of 352,792,000 (26.5%).
- Net income of 50,260,000 contributed positively to equity growth.
- Dividend payments of 59,368,000 reduced retained earnings.
- New share issuances of 360,000,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$50.26 Million | +2.98% |
| Dividends Paid | NT$59.37 Million | -3.53% |
| Share Issuances | NT$360.00 Million | +21.38% |
| Other Changes | NT$1.90 Million | +0.11% |
| Total Change | NT$- | 26.51% |
Book Value vs Market Value Analysis
This analysis compares Jia Jie Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.06x to 0.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$10.01 | NT$10.65 | x |
| 2018-12-31 | NT$10.27 | NT$10.65 | x |
| 2019-12-31 | NT$11.41 | NT$10.65 | x |
| 2020-12-31 | NT$10.22 | NT$10.65 | x |
| 2021-12-31 | NT$10.21 | NT$10.65 | x |
| 2022-12-31 | NT$9.83 | NT$10.65 | x |
| 2023-12-31 | NT$11.45 | NT$10.65 | x |
| 2024-12-31 | NT$13.12 | NT$10.65 | x |
| 2025-12-31 | NT$14.18 | NT$10.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jia Jie Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.35%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.12x
- Recent ROE (2.98%) is above the historical average (-0.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 3.98% | 4.74% | 0.51x | 1.66x | NT$-57.29 Million |
| 2016 | 1.24% | 1.86% | 0.38x | 1.76x | NT$-81.89 Million |
| 2017 | -33.64% | -44.48% | 0.39x | 1.91x | NT$-301.09 Million |
| 2018 | 0.35% | 0.62% | 0.36x | 1.58x | NT$-68.29 Million |
| 2019 | -3.52% | -7.14% | 0.40x | 1.23x | NT$-94.02 Million |
| 2020 | -3.51% | -11.81% | 0.27x | 1.09x | NT$-122.85 Million |
| 2021 | 0.59% | 2.20% | 0.24x | 1.13x | NT$-85.45 Million |
| 2022 | -0.61% | -1.72% | 0.32x | 1.12x | NT$-95.27 Million |
| 2023 | 13.77% | 43.32% | 0.24x | 1.35x | NT$39.46 Million |
| 2024 | 15.88% | 39.36% | 0.36x | 1.11x | NT$78.27 Million |
| 2025 | 2.98% | 10.35% | 0.26x | 1.12x | NT$-118.12 Million |
Industry Comparison
This section compares Jia Jie Biomedical Co Ltd's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $9,604,804,100
- Average return on equity (ROE) among peers: 5.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jia Jie Biomedical Co Ltd (4109) | NT$1.70 Billion | 3.98% | 0.13x | $39.84 Million |
| Wei Chuan Foods Corp (1201) | $7.23 Billion | 3.32% | 1.43x | $216.84 Million |
| Ve Wong Corp (1203) | $7.42 Billion | 5.80% | 0.41x | $332.51 Million |
| Great Wall Enterprise Co Ltd (1210) | $19.25 Billion | 3.07% | 1.08x | $1.34 Billion |
| Charoen Pokphand Enterprise Taiwan Co Ltd (1215) | $3.28 Billion | 8.30% | 0.69x | $961.26 Million |
| Uni-President Enterprises Corp (1216) | $39.49 Billion | 8.57% | 2.51x | $14.52 Billion |
| AGV Products Corp (1217) | $6.12 Billion | 2.17% | 1.00x | $148.16 Million |
| Taisun Enterprise Co Ltd (1218) | $3.51 Billion | 0.00% | 1.48x | $208.38 Million |
| Fwusow Industry Co Ltd (1219) | $4.44 Billion | 13.85% | 0.92x | $118.80 Million |
| Tai Roun Products Co Ltd (1220) | $1.69 Billion | 0.00% | 0.47x | $59.74 Million |
| Formosa Oilseed Processing Co Ltd (1225) | $3.60 Billion | 7.10% | 0.78x | $195.40 Million |
About Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jel… Read more